"Mitolactol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs.
| Descriptor ID |
D008936
|
| MeSH Number(s) |
D02.033.800.400.500 D09.853.400.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mitolactol".
Below are MeSH descriptors whose meaning is more specific than "Mitolactol".
This graph shows the total number of publications written about "Mitolactol" by people in this website by year, and whether "Mitolactol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mitolactol" by people in Profiles.
-
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. J Clin Oncol. 1997 Mar; 15(3):1063-70.
-
Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy. Pediatr Neurosurg. 1996 Oct; 25(4):174-81.
-
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer. 1984 May 01; 53(9):1841-4.
-
Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP). Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):33-8.